Real-world experience of larotrectinib in children, adolescents and young adults with TRK fusion solid tumors: The SACHA-France experience
Authors:
- 21 June 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 244, 116904
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK)European Journal of Cancer, 2026
- Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancerESMO Open, 2025
- Centralized Investigator Review of Radiological and Functional Imaging Reports in Real‐World Oncology Studies: The SACHA‐France ExperiencePediatric Blood & Cancer, 2024
- Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)ESMO Open, 2024
- Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France StudyJAMA Network Open, 2023
- TRK inhibitor activity and resistance in TRK fusion-positive cancers in adultsCancer Genetics, 2022
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsThe Lancet Oncology, 2020
- Resistance to TRK inhibition mediated by convergent MAPK pathway activationNature Medicine, 2019
- The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomasCancer, 2018
- ETV6–NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma studyPediatric Blood & Cancer, 2017